Is American Express a Buy, Sell or Hold?
American Express (NYSE:AXP) holds a notable place in Warren Buffett’s…
Sell
21
HBIO Quote, Financials, Valuation and Earnings
Last price:
$0.39
Seasonality move
:
-3.11%
Day range:
$0.38 - $0.42
52-week range:
$0.36 - $4.31
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
0.18x
P/B ratio:
0.27x
Volume:
289.1K
Avg. volume:
379.7K
1-year change:
-90.51%
Market cap:
$17.1M
Revenue:
$94.1M
EPS (TTM):
-$0.29
Analysts' Opinion
-
Consensus RatingHarvard Bioscience has received a consensus rating of Leans Bullish. The company's average rating is a Leans Bullish based on 1 Buy rating, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $4.50, Harvard Bioscience has an estimated upside of 1059.79% from its current price of $0.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $4.50 representing -- downside risk from its current price of $0.39.
Fair Value
-
According to the consensus of 2 analysts, Harvard Bioscience has 1059.79% upside to fair value with a price target of $4.50 per share.
HBIO vs. S&P 500
-
Over the past 5 trading days, Harvard Bioscience has overperformed the S&P 500 by 1.53% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Harvard Bioscience does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Harvard Bioscience revenues have been falling on a year-over-year basis for 7 quarters in a row. In the most recent quarter Harvard Bioscience reported revenues of $24.6M.
Earnings Growth
-
Harvard Bioscience has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Harvard Bioscience reported earnings per share of --.
Enterprise value:
49.9M
EV / Invested capital:
--
Price / LTM sales:
0.18x
EV / EBIT:
--
EV / Revenue:
0.53x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
-27.40x
Price / Operating cash flow:
185.32x
Enterprise value / EBITDA:
177.66x
Gross Profit (TTM):
$54.8M
Return On Assets:
-9.44%
Net Income Margin (TTM):
-13.18%
Return On Equity:
-18.36%
Return On Invested Capital:
-11.92%
Operating Margin:
-5.63%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Income Statement | ||||||
| Revenue | $113.3M | $112.3M | $94.1M | $28.2M | $24.6M | |
| Gross Profit | $60.8M | $66.1M | $54.8M | $16.3M | $14M | |
| Operating Income | -$7.2M | $1.9M | -$7.2M | $282K | -$1.4M | |
| EBITDA | $944K | $8M | -$1.3M | $1.5M | $3.2M | |
| Diluted EPS | -$0.23 | -$0.08 | -$0.29 | -$0.04 | -- | |
| Period Ending | 2020-12-31 | 2021-12-31 | 2022-12-31 | 2023-12-31 | 2024-12-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $51.7M | $61.6M | $51.1M | $49M | $45.1M | |
| Total Assets | $156.3M | $162.3M | $145.4M | $137.4M | $126.6M | |
| Current Liabilities | $21.1M | $25.3M | $23.2M | $26.5M | $55M | |
| Total Liabilities | $79.6M | $78.9M | $73.1M | $64.3M | $63.3M | |
| Total Equity | $76.7M | $83.4M | $72.2M | $73.1M | $63.3M | |
| Total Debt | $48M | $48.3M | $46.8M | $36.6M | $37M | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-12-31 | 2023-12-31 | 2024-12-31 | 2023-12-31 | 2024-12-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | $1.2M | $14M | $1.4M | $4.3M | $1.7M | |
| Cash From Investing | -$1.6M | -$1.8M | -$1.3M | -$1.1M | -$466K | |
| Cash From Financing | -$2.8M | -$12.1M | -$131K | -$4.1M | -$1.4M | |
| Free Cash Flow | -$438K | $11.7M | -$1.8M | $3.2M | $1.3M | |
HBIO
Sector
Market Cap
$17.1M
$35M
Price % of 52-Week High
--
42.2%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.81%
1-Year Price Total Return
-90.51%
-41.61%
Beta (5-Year)
1.468
0.742
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.40
200-day SMA
Sell
Level
$2.10
Bollinger Bands (100)
Sell
Level
0.75 - 2.13
Chaikin Money Flow
Buy
Level
490.8K
20-day SMA
Sell
Level
$0.49
Relative Strength Index (RSI14)
Sell
Level
27.50
ADX Line
Sell
Level
42.92
Williams %R
Buy
Level
-89.5205
50-day SMA
Sell
Level
$0.81
MACD (12, 26)
Sell
Level
-0.13
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Neutral
Level
4.1M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-0.4356)
Sell
CA Score
(Annual)
Level (-0.3974)
Buy
Beneish M-Score
(Annual)
Level (-3.1205)
Sell
Momentum Score
Level (1)
Sell
Ohlson Score
Level (1.6822)
Buy
Piotroski F Score
(Annual)
Level (4)
Buy
Quality Ratio Score
Level (6)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, pharmaceutical and therapy discovery, bioproduction, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, and Panlab. The majority of its revenue comes from the United States.
Stock Forecast FAQ
In the current month, HBIO has received 1 Buy ratings 1 Hold ratings, and 0 Sell ratings. The HBIO average analyst price target in the past 3 months is $4.50.
-
Where Will Harvard Bioscience Stock Be In 1 Year?
According to analysts, the consensus estimate is that Harvard Bioscience share price will rise to $4.50 per share over the next 12 months.
-
What Do Analysts Say About Harvard Bioscience?
Analysts are divided on their view about Harvard Bioscience share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Harvard Bioscience is a Sell and believe this share price will drop from its current level to $4.50.
-
What Is Harvard Bioscience's Price Target?
The price target for Harvard Bioscience over the next 1-year time period is forecast to be $4.50 according to 2 Wall Street analysts, 1 of them rates the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is HBIO A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Harvard Bioscience is a Leans Bullish. 1 of 2 analysts rates the stock a Leans Bullish at this time.
-
How Can I Buy Shares Of HBIO?
You can purchase shares of Harvard Bioscience via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Harvard Bioscience shares.
-
What Is The Harvard Bioscience Share Price Today?
Harvard Bioscience was last trading at $0.39 per share. This represents the most recent stock quote for Harvard Bioscience. Yesterday, Harvard Bioscience closed at $0.39 per share.
-
How To Buy Harvard Bioscience Stock Online?
In order to purchase Harvard Bioscience stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Baidu Stock a Sleeper AI Winner?
Although the recent policy decisions have gripped the market now,…
JPMorgan Is The Rally Over?
JPMorgan Chase (NYSE:JPM) share price is up 29% over the…
Stock Ideas
Sell
50
Is AAPL Stock a Buy?
Market Cap: $3T
P/E Ratio: 32x
Sell
47
Is MSFT Stock a Buy?
Market Cap: $2.7T
P/E Ratio: 31x
Sell
46
Is NVDA Stock a Buy?
Market Cap: $2.5T
P/E Ratio: 35x
Alerts
Sell
23
UNH alert for Apr 19
UnitedHealth Group [UNH] is down 22.4% over the past day.
Sell
32
MAN alert for Apr 19
ManpowerGroup [MAN] is down 19.07% over the past day.
Sell
24
GPN alert for Apr 19
Global Payments [GPN] is down 17.44% over the past day.
